EXTENDED REPORT

Incidence of lymphoma in a large primary care derived cohort of cases of inflammatory polyarthritis

J Franklin¹, M Lunt¹, D Bunn², D Symmons¹, A Silman¹

¹ ARC Epidemiology Research Unit, Manchester University Medical School, Manchester, UK
² Norfolk Arthritis Register, Norfolk and Norwich Hospital, UK

Correspondence to:
Professor Alan J Silman
Epidemiology Research Unit, The Medical School, Oxford Road, Manchester M13 9PT, UK; alan.silman{at}man.ac.uk

Objective: To determine the risk of lymphoma in a primary care derived cohort of new onset cases of inflammatory polyarthritis and assess the contribution of disease severity and standard immunosuppressive treatment.

Design: Prospective cohort study.

Methods: 2105 subjects with new onset inflammatory polyarthritis were recruited to the Norfolk Arthritis Register (NOAR) and followed annually for (median) 8.4 years. Occurrence of lymphoma was determined by annual morbidity review and linkage to the central hospital database serving the NOAR area. Cases of lymphoma were verified by record review. Standardised incidence ratios (SIRs) for lymphoma were calculated compared with the local, age, sex, and calendar year expected rates. Stratified analyses were undertaken for various markers of disease severity and treatment history.

Results: There were 11 cases of lymphoma during 15 548 person years of follow up, the majority of which were of large B cell type. Compared with the local population the SIR was 2.4 (95% confidence interval, 1.2 to 4.2). The risks in cases classified as rheumatoid arthritis, ever rheumatoid factor positive, or ever treated with DMARDs were all higher, the highest risk group being those treated with methotrexate: SIR = 4.9 (1.8 to 10.6).

Conclusions: There was a doubling in risk of lymphoma in new onset cases of inflammatory polyarthritis. Patients with the most severe disease were twice as likely as other patients to develop lymphoma. These results need to be taken into account when considering reported increased risks of lymphoma compared to background population risk in users of new biological agents.

Abbreviations: DMARD, disease modifying antirheumatic drug; HAQ, health assessment questionnaire; NHL, non-Hodgkin’s lymphoma; NOAR, Norfolk Arthritis Register; RF, rheumatoid factor; SIR, standardised incidence ratio

Keywords: inflammatory polyarthritis; lymphoma; primary care

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Simon, T A, Smitten, A L, Franklin, J, Askling, J, Lacaille, D, Wolfe, F, Hochberg, M C, Qi, K, Suissa, S (2009). Malignancies in the rheumatoid arthritis abatacept clinical development programme: an epidemiological assessment. Ann Rheum Dis 68: 1819-1826 [Abstract] [Full Text]  
• Sokol, H, Beaugerie, L (2009). Inflammatory bowel disease and lymphoproliferative disorders: the dust is starting to settle. Gut 58: 1427-1436 [Abstract] [Full Text]  
• Askling, J, Baecklund, E, Granath, F, Geborek, P, Fored, M, Backlin, C, Bertilsson, L, Coster, L, Jacobsson, L T, Lindblad, S, Lysholm, J, Rantapaa-Dahlqvist, S, Saxne, T, van Vollenhoven, R, Klareskog, L, Feltelius, N (2009). Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register. Ann Rheum Dis 68: 648-653 [Abstract] [Full Text]  
• Ekstrom Smedby, K., Vajdic, C. M., Falster, M., Engels, E. A., Martinez-Maza, O., Turner, J., Hjalgrim, H., Vineis, P., Seniori Costantini, A., Bracci, P. M., Holly, E. A., Willett, E., Spinelli, J. J., La Vecchia, C., Zheng, T., Becker, N., De Sanjose, S., Chiu, B. C.-H., Dal Maso, L., Cocco, P., Maynadie, M., Foretova, L., Staines, A., Brennan, P., Davis, S., Severson, R., Cerhan, J. R., Breen, E. C., Birmann, B., Grulich, A. E., Cozen, W. (2008). Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium. Blood 111: 4029-4038 [Abstract] [Full Text]  
• Herrinton, L J, Liu, L, Shoor, S, Mines, D (2008). Risk of lymphoproliferative cancer among patients with severe rheumatoid arthritis, 1996-2002. Ann Rheum Dis 67: 574-575 [Full Text]  
• Augustsson, J., Eksborg, S., Ernestam, S., Gullstrom, E., van Vollenhoven, R. (2007). Low-dose glucocorticoid therapy decreases risk for treatment-limiting infusion reaction to infliximab in patients with rheumatoid arthritis. Ann Rheum Dis 66: 1462-1466 [Abstract] [Full Text]  
• Symmons, D. P. M. (2007). Lymphoma and rheumatoid arthritis--again. Rheumatology (Oxford) 46: 1-2 [Full Text]  
• Smedby, K. E., Baecklund, E., Askling, J. (2006). Malignant Lymphomas in Autoimmunity and Inflammation: A Review of Risks, Risk Factors, and Lymphoma Characteristics.. Cancer Epidemiol. Biomarkers Prev. 15: 2069-2077 [Abstract] [Full Text]